


APPENDIX A


CLEAN COPY OF CLAIMS AS AMENDED HEREIN

98. A compound of the formula:




namely 2-[(2-aminoethyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine.

99. A compound of the formula:



namely 2-[(2-aminopropyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine.

106. A compound of the formula:



namely 2-{[9-(methylethyl)-6-(3-quinolylamino)purin-2-yl]amino}ethan-1-ol.

109. A method of inhibiting a cell cycle kinase characterized as CDK2,
comprising administering to a mammal in need thereof a therapeutically effective dose of

{2-[(2-aminoethyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine,
{2-[(2-aminopropyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine,
or 2-{[9-(methylethyl)-6-(3-quinolylamino)purin-2-yl]amino}ethan-1-ol.

110. The method of claim 109, wherein the inhibition of CDK-2 kinase treats a proliferative disease in which pathogenesis involves abnormal cell proliferation.